CL2012001980A1 - Uso de un anticuerpo monoclonal anti-cd44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (hnscc) en un mamífero, donde el hnscc se distingue según la expresión de cd44. - Google Patents

Uso de un anticuerpo monoclonal anti-cd44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (hnscc) en un mamífero, donde el hnscc se distingue según la expresión de cd44.

Info

Publication number
CL2012001980A1
CL2012001980A1 CL2012001980A CL2012001980A CL2012001980A1 CL 2012001980 A1 CL2012001980 A1 CL 2012001980A1 CL 2012001980 A CL2012001980 A CL 2012001980A CL 2012001980 A CL2012001980 A CL 2012001980A CL 2012001980 A1 CL2012001980 A1 CL 2012001980A1
Authority
CL
Chile
Prior art keywords
hnscc
monoclonal antibody
mammal
neck
expression
Prior art date
Application number
CL2012001980A
Other languages
English (en)
Inventor
Cruz Luis A-G Da
Elizabeth Jene Franzmann
Original Assignee
Hoffmann La Roche
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001980(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Univ Miami filed Critical Hoffmann La Roche
Publication of CL2012001980A1 publication Critical patent/CL2012001980A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Uso de un anticuerpo monoclonal anti-CD44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (HNSCC) en un mamífero, donde el HNSCC se distingue según la expresión de CD44; anticuerpo monoclonal anti-CD44; anticuerpo humanizado anti-CD44; kit para detectar la presencia de HNSCC en una muestra.
CL2012001980A 2010-02-04 2012-07-17 Uso de un anticuerpo monoclonal anti-cd44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (hnscc) en un mamífero, donde el hnscc se distingue según la expresión de cd44. CL2012001980A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30144910P 2010-02-04 2010-02-04

Publications (1)

Publication Number Publication Date
CL2012001980A1 true CL2012001980A1 (es) 2012-11-23

Family

ID=43858306

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001980A CL2012001980A1 (es) 2010-02-04 2012-07-17 Uso de un anticuerpo monoclonal anti-cd44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (hnscc) en un mamífero, donde el hnscc se distingue según la expresión de cd44.

Country Status (29)

Country Link
US (2) US20130224108A1 (es)
EP (1) EP2531527B1 (es)
JP (2) JP5763105B2 (es)
KR (1) KR20130042466A (es)
CN (1) CN102741292B (es)
AU (1) AU2011212485B2 (es)
BR (1) BR112012019475A8 (es)
CA (1) CA2786337A1 (es)
CL (1) CL2012001980A1 (es)
CR (1) CR20120429A (es)
DK (1) DK2531527T3 (es)
EC (1) ECSP12012138A (es)
ES (1) ES2460945T3 (es)
HR (1) HRP20140513T1 (es)
IL (1) IL220092A (es)
MA (1) MA34010B1 (es)
MX (1) MX2012008699A (es)
MY (1) MY157532A (es)
NZ (1) NZ600079A (es)
PE (1) PE20130380A1 (es)
PL (1) PL2531527T3 (es)
PT (1) PT2531527E (es)
RS (1) RS53327B (es)
RU (1) RU2599447C2 (es)
SG (2) SG10201505118PA (es)
SI (1) SI2531527T1 (es)
TW (1) TW201130512A (es)
WO (1) WO2011095498A1 (es)
ZA (1) ZA201205649B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741292B (zh) * 2010-02-04 2015-10-21 霍夫曼-拉罗奇有限公司 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体
AU2012328512A1 (en) * 2011-10-26 2014-05-08 The Regents Of The University Of California CD44 monoclonal antibody for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies
EP2788024A1 (en) * 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
US20150044232A1 (en) * 2013-06-12 2015-02-12 Hoffmann-La Roche Inc. Markers for the responsiveness to anti-cd44 antibodies
WO2015017692A1 (en) * 2013-07-31 2015-02-05 University Of Miami Compositions and methods for identifying a risk of cancer in a subject
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
KR102215384B1 (ko) * 2014-06-11 2021-02-15 (재) 스크립스코리아항체연구원 CD44v3 도메인 3 및 도메인 6 특이적 단일클론 항체 및 그 용도
TWI535452B (zh) 2015-01-23 2016-06-01 長庚醫療財團法人 使用抗－ｃｄ４４中和抗體來治療和／或預防心房顫動
WO2021233962A1 (en) 2020-05-19 2021-11-25 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome
EP4301782A1 (en) * 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE19545472A1 (de) * 1995-12-06 1997-06-12 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
CN1541226A (zh) 2001-05-18 2004-10-27 ���ָ��Ӣ��ķ�������Ϲ�˾ CD44v6特异性的抗体
US20030103985A1 (en) * 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
CN102741292B (zh) * 2010-02-04 2015-10-21 霍夫曼-拉罗奇有限公司 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体

Also Published As

Publication number Publication date
US20130224108A1 (en) 2013-08-29
WO2011095498A1 (en) 2011-08-11
MX2012008699A (es) 2012-09-12
IL220092A0 (en) 2012-09-24
IL220092A (en) 2016-02-29
PE20130380A1 (es) 2013-03-30
CN102741292A (zh) 2012-10-17
AU2011212485A1 (en) 2012-07-19
JP2015155409A (ja) 2015-08-27
CR20120429A (es) 2012-12-06
EP2531527A1 (en) 2012-12-12
NZ600079A (en) 2013-07-26
JP2013518848A (ja) 2013-05-23
KR20130042466A (ko) 2013-04-26
PT2531527E (pt) 2014-05-16
MA34010B1 (fr) 2013-02-01
BR112012019475A2 (pt) 2017-01-10
CN102741292B (zh) 2015-10-21
ES2460945T3 (es) 2014-05-16
DK2531527T3 (da) 2014-05-05
HRP20140513T1 (hr) 2014-07-18
MY157532A (en) 2016-06-15
EP2531527B1 (en) 2014-03-19
BR112012019475A8 (pt) 2017-12-26
JP5763105B2 (ja) 2015-08-12
RS53327B (en) 2014-10-31
RU2012137380A (ru) 2014-03-10
US20150374848A1 (en) 2015-12-31
ZA201205649B (en) 2015-01-28
CA2786337A1 (en) 2011-08-11
JP6037149B2 (ja) 2016-11-30
AU2011212485B2 (en) 2014-04-17
ECSP12012138A (es) 2012-09-28
TW201130512A (en) 2011-09-16
PL2531527T3 (pl) 2014-08-29
RU2599447C2 (ru) 2016-10-10
SI2531527T1 (sl) 2014-07-31
SG182704A1 (en) 2012-08-30
SG10201505118PA (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CL2012001980A1 (es) Uso de un anticuerpo monoclonal anti-cd44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (hnscc) en un mamífero, donde el hnscc se distingue según la expresión de cd44.
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
EA201492101A1 (ru) Антитела против fcrn
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
CL2012002328A1 (es) Anticuerpo aislado anti-tat419 que inhibe la proliferación celular; ácido nucleico que lo codifica; célula que lo produce; método para identificar anticuerpos que unen un epítopo antigénico tat419; método para inhibir la proliferación de una célula que expresa un péptido tat419; y su uso en el tratamiento de tumores cancerígenos.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EA201290413A1 (ru) МУТИРОВАННЫЕ Fc АНТИТЕЛ С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
EA201600474A1 (ru) Комбинированная терапия с использованием антитела к ang2 и агониста cd40
CL2014001217A1 (es) Polinucleotido que codifica un polipeptido de neurotoxina que muestra una menor duracion del efecto biologico en un sujeto; vector; celula huesped; polipeptido codificado; metodo de fabricacion del polipeptido; anticuerpo que se une al polipeptido; y su uso.
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
CL2011002417A1 (es) Anticuerpo especifico para fcrh5, receptor de superficie celular con homologia con las familias del receptor fc; anticuerpo anti-fcrh5 humanizado; polinucleotido que lo codifica; vector; celular huesped; metodo de obtencion; inmunoconjugado; composicion farmaceutica; y su uso para tratar cancer.
NZ628314A (en) Cd47 antibodies and methods of use thereof
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
GT201300149A (es) Proteinas de union al tnf-a
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
EA201590528A1 (ru) Антитела к мсам и способы их применения
CL2012002741A1 (es) Metodo para determinar en una muestra de sangre la presencia de vitamina d libre; inmunoensayo para detrminar presencia de vitamina d libre en sangre; kit para efectuar inmunoensayo.
ECSP12012307A (es) Proteínas de unión a il-1
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
AR098126A1 (es) Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
AR082518A1 (es) Anticuerpos contra il-18r1 y usos de los mismos
PE20160657A1 (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn